Arthur Lahr served from 2017 to 2021 as Chief Executive Officer of Kiadis Pharma and from 2004 to 2011 as Chief Strategy Officer at Crucell, and both companies executed various successful strategic pivots during his tenure. 

In 2019 Kiadis took the decision to drop its lead T-cell transplant program midway through a phase 3 trial. The action saw Kiadis lay off half of its staff. Instead of giving up and closing shop, Kiadis switched its attention to earlier-stage natural killer (NK) cell therapies against solid tumors and hematological cancers, a space they had moved into earlier in 2019 through the acquisition of Cytosen Therapeutics. In April 2021 Kiadis was sold to Sanofi, based on that new platform.

Between 2001 and 2011 Crucell performed multiple successful strategic moves: from oncology (2001-2003), to protein production (2003-2011) and infectious disease (2004-2011), to ultimately become a global fully integrated commercial stage vaccine business (2007-2011). This eventually led to the acquisition of Crucell by Johnson & Johnson in 2011. 

Before moving into biotech Arthur was a consultant at McKinsey & Company and an engineer at Unilever NV. Arthur also served as a member of the supervisory board of Sanquin, a Dutch national plasma and blood product supplier, from 2013 to 2019.